Condition
Birt-Hogg-Dube Syndrome
Total Trials
6
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Recruiting2
Completed1
Enrolling By Invitation1
Unknown1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06330350Recruiting
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
NCT06330324Enrolling By Invitation
Reproductive Options in Inherited Skin Diseases
NCT03749980Recruiting
MyVHL: Patient Natural History Study
NCT03040115CompletedPrimary
Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome
NCT05534854Unknown
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes
NCT02504892Phase 2Terminated
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Showing all 6 trials